BeiGene Announces Employee Share Purchase Plan with Up to 4 Million Shares to be Sold

BeiGene plans to sell up to 4 million shares through an employee share purchase plan. The biotechnology company is focused on discovering and developing oncology treatments for various cancers worldwide. It has approved medicines including BRUKINSA, TEVIMBRA, and pamiparib. BeiGene is also commercializing cancer medicines such as XGEVA, BLINCYTO, and KYPROLIS in China under an exclusive license from Amgen.

Private equity investor firm Royalty Pharma has acquired a royalty interest in Amgen’s Imdelltra (tarlatamab-dlle) from BeOne Medicines (formerly known as BeiGene) in a deal worth up to $950 million [1]. Imdelltra is an immunotherapy prescribed to adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC), a type of cancer that affects more than 200,000 people annually in the United States [1]. Following a successful Phase II clinical trial (NCT05060016), the US Food and Drug Administration (FDA) granted a "first of its kind" accelerated approval to Imdelltra in May 2024 [1].

Royalty Pharma will pay China-based BeOne Medicines $885 million upfront, with the possibility of purchasing additional royalties for up to $65 million [1]. As part of the agreement, BeOne Medicines will retain exclusive rights to distribute the immunotherapy in China. Pablo Legorreta, CEO of Royalty Pharma, expressed excitement about the deal, stating that Imdelltra is reshaping the treatment paradigm for patients with small cell lung cancer, a highly aggressive disease with few treatment options [1].

The immunotherapy has seen significant success upon market entry, with sales reaching $215 million in the first six months of 2025 alone, exceeding analysts' predictions by 41% [1]. At the current growth rate, revenue generated by Amgen’s development is forecasted to exceed $2.8 billion by 2035 [1]. Royalty Pharma will receive 7% royalty on worldwide net sales of Imdelltra [1].

This acquisition is part of Royalty Pharma's strategy to bolster its oncology portfolio. The company entered a royalty agreement worth $500 million for the US sales of Ferring Pharmaceuticals' Adstiladrin in 2023 and later acquired a royalty interest in vorasidenib (commercially known as Voranigo) for $905 million in 2024 [1].

Separately, BeiGene, the biotechnology company that originally developed Imdelltra, plans to sell up to 4 million shares through an employee share purchase plan [2]. BeiGene is focused on discovering and developing oncology treatments for various cancers worldwide and has approved medicines including BRUKINSA, TEVIMBRA, and pamiparib [2]. The company is also commercializing cancer medicines such as XGEVA, BLINCYTO, and KYPROLIS in China under an exclusive license from Amgen [2].

References:
[1] https://www.bioxconomy.com/partnering/royalty-pharma-acquires-amgen-s-lung-cancer-treatment-in-950m-deal
[2] https://www.bioxconomy.com/bei-gene-plans-to-sell-up-to-4-million-shares-through-an-employee-share-purchase-plan